Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA places partial clinical hold on planned NY-ESO SPEAR T-cell therapy study

Aug. 4, 2016

Amgen and Advaxis enter global collaboration to develop cancer immunotherapies

Aug. 4, 2016

Keytruda approved in Europe for patients with advanced NSCLC whose tumors express PD-L1

Aug. 3, 2016

Phase III ALCANZA trial of Adcetris in CTCL meets primary endpoint

Aug. 2, 2016

Adaptimmune Therapeutics gains access to EMA's PRIME initiative for T-cell therapy

July 29, 2016

Western Oncolytics and Pfizer enter immuno-oncology research collaboration

July 29, 2016

Ono seeks Japanese approval for Opdivo for head and neck cancer

July 29, 2016

Tesaro initiates phase I study of TSR-022 for advanced solid tumors

July 29, 2016

EMA grants PRIME designation to DNX-2401 for recurrent glioblastoma

July 28, 2016

Janssen, BMS enter immuno-oncology collaboration in lung cancer

July 28, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...